More Evidence That ACAT Is the Wrong Target for Lipid Lowering

MedPage -- Analysis of data from an aborted trial of a failed investigational drug provided still more evidence that attempting to control cholesterol by inhibiting an enzyme involved in its transport may be a bad idea.